78 related articles for article (PubMed ID: 11820605)
21. Immunohistochemical detection of p53 protein in human prostatic cancer.
Henke RP; Krüger E; Ayhan N; Hübner D; Hammerer P; Huland H
J Urol; 1994 Oct; 152(4):1297-301. PubMed ID: 8072122
[TBL] [Abstract][Full Text] [Related]
22. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression?
Cheng L; Leibovich BC; Bergstralh EJ; Scherer BG; Pacelli A; Ramnani DM; Zincke H; Bostwick DG
Cancer; 1999 Jun; 85(11):2455-9. PubMed ID: 10357418
[TBL] [Abstract][Full Text] [Related]
23. Levels of expression of p27KIP1 protein in human prostate and prostate cancer: an immunohistochemical analysis.
Erdamar S; Yang G; Harper JW; Lu X; Kattan MW; Thompson TC; Wheeler TM
Mod Pathol; 1999 Aug; 12(8):751-5. PubMed ID: 10463475
[TBL] [Abstract][Full Text] [Related]
24. p53 expression as a prognostic determinant in resected distal bile duct carcinoma.
Rijken AM; Offerhaus GJ; Polak MM; Gouma DJ; van Gulik TM
Eur J Surg Oncol; 1999 Jun; 25(3):297-301. PubMed ID: 10336811
[TBL] [Abstract][Full Text] [Related]
25. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy.
Oxley JD; Winkler MH; Parry K; Brewster S; Abbott C; Gillatt DA
BJU Int; 2002 Jan; 89(1):27-32. PubMed ID: 11849156
[TBL] [Abstract][Full Text] [Related]
26. p53 expression and clinical outcome in prostate cancer.
Thomas DJ; Robinson M; King P; Hasan T; Charlton R; Martin J; Carr TW; Neal DE
Br J Urol; 1993 Nov; 72(5 Pt 2):778-81. PubMed ID: 8281412
[TBL] [Abstract][Full Text] [Related]
27. [Recurrence following radical surgery for prostatic cancer. Analysis of clinical, biological and anatomo-pathological prognostic factors].
Feyaerts A; Delrée A; Lorge F; Opsomer RJ; Wese FX; Van Cangh PJ; Draguet AP; Cosyns JP
Acta Urol Belg; 1997 Mar; 65(1):11-8. PubMed ID: 9245198
[TBL] [Abstract][Full Text] [Related]
28. Cysteine-rich secretory protein 3 and β-microseminoprotein on prostate cancer needle biopsies do not have predictive value for subsequent prostatectomy outcome.
Hoogland AM; Dahlman A; Vissers KJ; Wolters T; Schröder FH; Roobol MJ; Bjartell AS; van Leenders GJ
BJU Int; 2011 Oct; 108(8):1356-62. PubMed ID: 21410630
[TBL] [Abstract][Full Text] [Related]
29. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneous expression of E-cadherin and p53 in prostate cancer: clinical implications. BIOMED-II Markers for Prostate Cancer Study Group.
Ruijter E; van de Kaa C; Aalders T; Ruiter D; Miller G; Debruyne F; Schalken J
Mod Pathol; 1998 Mar; 11(3):276-81. PubMed ID: 9521475
[TBL] [Abstract][Full Text] [Related]
31. Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Murphy GP; Busch C; Abrahamsson PA; Epstein JI; McNeal JE; Miller GJ; Mostofi FK; Nagle RB; Nordling S; Parkinson C
Scand J Urol Nephrol Suppl; 1994; 162():7-42; discussion 115-27. PubMed ID: 7817162
[TBL] [Abstract][Full Text] [Related]
32. p27(kip1) and Ki-67 (MIB1) immunohistochemical expression in radical prostatectomy specimens of patients with clinically localized prostate cancer.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Tenta R; Koutsilieris M
In Vivo; 2005; 19(5):911-20. PubMed ID: 16097446
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Magi-Galluzzi C; Zhou M; Reuther AM; Dreicer R; Klein EA
Cancer; 2007 Sep; 110(6):1248-54. PubMed ID: 17674353
[TBL] [Abstract][Full Text] [Related]
34. Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression.
Yang G; Stapleton AM; Wheeler TM; Truong LD; Timme TL; Scardino PT; Thompson TC
Clin Cancer Res; 1996 Feb; 2(2):399-401. PubMed ID: 9816183
[TBL] [Abstract][Full Text] [Related]
35. Expression of p53 protein in prostate cancers of different histologic types.
Losi L; Di Gregorio C; Brausi M; Fante R; Hurlimann J
Pathol Res Pract; 1994 Apr; 190(4):384-8. PubMed ID: 8078807
[TBL] [Abstract][Full Text] [Related]
36. [Cancer of the prostate: evaluation of the expression of the mutated protein of the 53 tumor suppressor gene].
Rivera P; Ibacache G; García M; Roa I; Orio M
Actas Urol Esp; 1997 Oct; 21(9):822-6. PubMed ID: 9471864
[TBL] [Abstract][Full Text] [Related]
37. Microvascular invasion of the seminal vesicles in adenocarcinoma of the prostate.
Graham SD; Napalkov P; Watts L; Salomao D; Bostwick DG
Prostate; 1996 Jun; 28(6):359-63. PubMed ID: 8650072
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of Bcl-2 in clinically localized prostate cancer.
Bubendorf L; Sauter G; Moch H; Jordan P; Blöchlinger A; Gasser TC; Mihatsch MJ
Am J Pathol; 1996 May; 148(5):1557-65. PubMed ID: 8623924
[TBL] [Abstract][Full Text] [Related]
39. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy.
Scherr DS; Vaughan ED; Wei J; Chung M; Felsen D; Allbright R; Knudsen BS
J Urol; 1999 Jul; 162(1):12-6; discussion 16-7. PubMed ID: 10379729
[TBL] [Abstract][Full Text] [Related]
40. Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 Image analysis system, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.
Veltri RW; Partin AW; Epstein JE; Marley GM; Miller CM; Singer DS; Patton KP; Criley SR; Coffey DS
J Cell Biochem Suppl; 1994; 19():249-58. PubMed ID: 7529856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
